Education
About Us
Working with TipRanks
Follow Us
JW (Cayman) Therapeutics Co. Ltd. (HK:2126)
:2126
RESEARCH TOOLSreports
2126 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$1.19 - HK$6.44
Previous CloseN/A
Volume104.00K
Average Volume (3M)6.47M
Market Cap
HK$2.51B
Enterprise ValueHK$161.53M
Total Cash (Recent Filing)HK$757.38M
Total Debt (Recent Filing)HK$422.40M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Mar 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding416,359,860
10 Day Avg. Volume5,103,446
30 Day Avg. Volume6,467,509
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.00Price Target Upside-0.50% Downside
Rating ConsensusHold
Number of Analyst Covering0
JW (Cayman) Therapeutics Co. Ltd. News
2126 FAQ
What was JW (Cayman) Therapeutics Co. Ltd.’s price range in the past 12 months?
JW (Cayman) Therapeutics Co. Ltd. lowest stock price was HK$1.19 and its highest was HK$6.44 in the past 12 months.
What is JW (Cayman) Therapeutics Co. Ltd.’s market cap?
JW (Cayman) Therapeutics Co. Ltd.’s market cap is HK$2.51B.
When is JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date?
JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date is Mar 25, 2026 which is in 208 days.
How were JW (Cayman) Therapeutics Co. Ltd.’s earnings last quarter?
JW (Cayman) Therapeutics Co. Ltd. released its earnings results on Aug 27, 2025. The company reported -HK$0.697 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.697.
Is JW (Cayman) Therapeutics Co. Ltd. overvalued?
According to Wall Street analysts JW (Cayman) Therapeutics Co. Ltd.’s price is currently Overvalued.
Does JW (Cayman) Therapeutics Co. Ltd. pay dividends?
JW (Cayman) Therapeutics Co. Ltd. does not currently pay dividends.
What is JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate?
JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JW (Cayman) Therapeutics Co. Ltd. have?
JW (Cayman) Therapeutics Co. Ltd. has 416,359,860 shares outstanding.
What happened to JW (Cayman) Therapeutics Co. Ltd.’s price movement after its last earnings report?
JW (Cayman) Therapeutics Co. Ltd. reported an EPS of -HK$0.697 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.319%.
Which hedge fund is a major shareholder of JW (Cayman) Therapeutics Co. Ltd.?
Currently, no hedge funds are holding shares in HK:2126
JW (Cayman) Therapeutics Co. Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
363.84%
12-Months-Change
Fundamentals
Return on Equity
-41.34%
Trailing 12-Months
Asset Growth
-24.32%
Trailing 12-Months
Company Description
JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd. (2126) is a biotechnology company focused on developing, manufacturing, and commercializing cell-based immunotherapies for cancer treatment. The company operates primarily in the healthcare and biotechnology sectors, with a core emphasis on chimeric antigen receptor T-cell (CAR-T) therapies. JW Therapeutics aims to innovate and provide transformative treatments for patients by leveraging cutting-edge biotechnological advancements and research in immunotherapy.
Technical Analysis
Alphamab Oncology
―
Lepu Biopharma Co. Ltd. Class H
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
CStone Pharmaceuticals
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Ownership Overview
―
Insiders
0.07%
Mutual Funds
― Other Institutional Investors
99.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---